



**LEARNING OBJECTIVE:** Readers will routinely offer vaccination against human papillomavirus and screen women for cervical cancer

**CYNTHIA ARVIZO, MD**

Department of Obstetrics and Gynecology,  
Vanderbilt University Medical Center,  
Nashville, TN

**HAIDER MAHDI, MD**

Department of Obstetrics and Gynecology, Women's  
Health Institute, Cleveland Clinic; Assistant Professor,  
Cleveland Clinic Lerner College of Medicine of Case  
Western Reserve University, Cleveland, OH

# Disparities in cervical cancer in African American women: What primary care physicians can do

## ABSTRACT

African American women are disproportionately affected by cervical cancer, with higher rates of incidence and mortality than white women. Most of the difference would disappear with equal treatment. As usual, primary care providers are on the front lines.

## KEY POINTS

Vaccination against human papillomavirus (HPV) is recommended for females ages 9 to 26 and males age 11 or 12. Three vaccines are available: a 2-valent, a 4-valent, and a newer 9-valent preparation.

HPV vaccination can now be given in a 2-dose series administered 6 to 12 months apart for patients who are ages 9 through 14 at the time of the first dose and are immunocompetent. Other patients should receive a 3-dose series, including patients who received 2 doses less than 5 months apart.

Cytologic screening (Papanicolaou testing) by itself is recommended every 3 years between the ages of 21 and 30. After age 30, combined screening with cytology and testing for HPV is recommended every 5 years.

Concomitant risk factors for cervical cancer such as human immunodeficiency virus infection and tobacco use should also be addressed during office visits.

**A**FRICAN AMERICAN, HISPANIC, American Indian, and Alaskan Native women continue to be disproportionately affected by cervical cancer compared with white women. From 2006 to 2010, the incidence of cervical cancer in African American women was 10.3 per 100,000; in white women it was 7.2.<sup>1</sup> The mortality rate from cervical cancer in African American women is twice that in white women.<sup>1</sup> Although cervical cancer rates have decreased nationwide, significant racial health disparities persist.

*See related editorial, page 795*

As the first-line healthcare providers for many women, the primary care physician and the general obstetrician-gynecologist are optimally positioned to reduce these disparities.

Cervical cancer is the third most common gynecologic cancer, after uterine and ovarian cancer. Nearly 13,000 new cases are diagnosed each year in the United States, and more than 4,000 women die of it.<sup>2</sup> Fortunately, cervical cancer can be significantly prevented with adequate screening and vaccination against human papillomavirus (HPV).

## ■ WHY ARE BLACK WOMEN MORE LIKELY TO DIE OF CERVICAL CANCER?

**Later stage at diagnosis.** African American women are more likely to present with advanced cervical cancer than non-Hispanic white women.<sup>3-6</sup>

**Less-aggressive treatment.** African American women are more likely to receive no treatment after a cancer diagnosis.<sup>6</sup> Differences in treatment may be attributed to comorbid

doi:10.3949/ccjm.84a.15115

conditions, stage at cancer diagnosis, and patient refusal.<sup>5,7</sup>

**Less access to care.** A study from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute looked at 7,267 women (4,431 non-Hispanic white women, 1,830 Hispanic white women, and 1,006 non-Hispanic African American women) who were diagnosed with primary invasive cervical cancer from 1992 to 1996 and followed through 2000. African American women had a 19% higher mortality rate compared with non-Hispanic white women during follow-up despite adjusting for age, stage, histology, and time of first treatment.<sup>8</sup>

However, a later study from the same program found no such difference after 1995, when the data were adjusted for marital status, disease stage, age, treatment, grade, and histology.<sup>6</sup>

Equal access to healthcare may eliminate most of the disparity.<sup>7</sup> A study in women with cervical cancer who sought treatment within the United States military healthcare system found no difference in treatment or 5- and 10-year survival rates between African American and white women.<sup>5</sup> Equal access to comprehensive healthcare eliminated any disparity once cervical cancer was diagnosed.

## ■ CERVICAL CANCER SCREENING

The value of cervical cancer screening and prevention is well established. In 1941, Papanicolaou reported that cervical cancer could be detected from vaginal smears.<sup>9</sup> Since the development and widespread implementation of the “Pap” smear, cervical cancer rates have decreased dramatically in the United States.

Another major advance was the discovery that persistent infection with HPV is necessary for the development of cervical cancer, precancerous lesions, and genital warts.<sup>10</sup>

With advancing research, guidelines for cervical cancer screening have changed considerably over the years. Today, combined cervical cytologic and HPV testing is the mainstay. (Isolated HPV testing is generally not available outside clinical trials.)

### Who should be screened?

Previous recommendations called for women to undergo Pap testing when they first became sexually active and then every year. However,

cervical lesions are likely to regress in young women.<sup>11</sup> One study found that 28% of cervical intimal neoplasia (CIN) grade 2 and 3 lesions spontaneously regressed by 15 weeks, although lesions associated with HPV 16 infection were less likely to regress than with other HPV types.<sup>12</sup> A study of college women found that HPV infection persisted in only 9% of women after 24 months.<sup>13</sup>

To minimize unnecessary treatment of young women with dysplasia, the American Society for Colposcopy and Cervical Pathology in 2012 recommended cytologic screening for all women 21 years or older, regardless of age at first sexual encounter.<sup>14</sup> Screening intervals were changed from every year to every 3 years until age 30, at which time cotesting with cytology and HPV testing is performed every 5 years. Routine cotesting is not recommended for women younger than 30, who have a high likelihood of HPV infection and spontaneous regression.

In 2014, the US Food and Drug Administration approved primary HPV screening (ie, testing for HPV first, and then performing cytology in samples that test positive) for women age 25 and older.<sup>15</sup>

Patients who need further evaluation and testing should be referred for colposcopy. The current guidelines for patients who have abnormal results on cervical cancer screening<sup>16</sup> can be reviewed at [www.asccp.org/asccp-guidelines](http://www.asccp.org/asccp-guidelines).

As screening guidelines continue to evolve, primary care physicians will need to stay current and also help educate their patients. For example, many of our patients have undergone annual Pap screening for most of their lives and may not yet know about the new testing intervals.

### Are there disparities in screening and follow-up?

Disparities in screening and follow-up may exist, but the evidence is not clear-cut.

In a 2013 National Health Interview Survey report, the rates of cervical cancer screening with Pap tests did not differ between African American and white women.<sup>17</sup> However, the information on Pap testing was based on a single question asking participants if they had had a Pap test in the last 3 years. In our experience, patients may confuse Pap tests with

**Equal access to healthcare may eliminate most of the disparity**

TABLE 1

**HPV vaccines available in the United States**

| Vaccine                         | HPV types covered                 |
|---------------------------------|-----------------------------------|
| <b>2-valent</b><br>(Cervarix)   | 16, 18                            |
| <b>4-valent</b><br>(Gardasil)   | 6, 11, 16, 18                     |
| <b>9-valent</b><br>(Gardasil-9) | 6, 11, 16, 18, 31, 33, 45, 52, 58 |

speculum examinations.

Once women are screened, adequate and timely follow-up of abnormal results is key.

In a study from the National Breast and Cervical Cancer Early Detection Program,<sup>18</sup> women who had cytology findings of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions were to undergo repeat Pap testing every 4 to 6 months for 2 years. African American women were the least likely to have a follow-up Pap smear compared with other racial groups.

On the other hand, there was no difference related to race in follow-up rates of abnormal Pap tests in women ages 47 to 64 in the South Carolina Breast and Cervical Cancer Early Detection Program.<sup>19</sup>

In a study in an urban population (predominantly African American), the overall follow-up rate was only 26% at 12 months from an initial abnormal Pap smear. This study did not find any differences in follow-up according to race or ethnicity; however, it had insufficient power to detect a difference because only 15% of the study participants were white.<sup>20</sup>

**What is in a genotype?**

HPV is implicated in progression to both squamous cell carcinoma and adenocarcinoma of the cervix. Worldwide, HPV genotypes 16 and 18 are associated with 73% of cases of invasive cervical cancer; most of the remainder are associated with, in order of decreasing prevalence, genotypes 58, 33, 45, 31, 52, 35, 59, 39, 51, and 56.<sup>21</sup>

High-grade cervical lesions in African American women may less often be positive

for HPV 16 and 18 than in white women.<sup>22,23</sup> On the other hand, the proportion of non-Hispanic black women infected with HPV 35 and 58 was significantly higher than in non-Hispanic white women.<sup>22</sup> Regardless, HPV screening is recommended for women of all races and ethnicities.

The 2-valent and 4-valent HPV vaccines do not cover HPV 35 or 58. The newer 9-valent vaccine covers HPV 58 (but not 35) and so may in theory decrease any potential disparity related to infection with a specific oncogenic subtype.

**THE ROLE OF PREVENTION****HPV vaccination**

Currently, 3 vaccines against HPV are available in the United States, a 2-valent, a 4-valent, and since 2015, a 9-valent preparation (Table 1).

The Females United to Unilaterally Reduce Endo/Ectocervical Disease study demonstrated that the 4-valent vaccine was highly effective against cervical intraepithelial neoplasia due to HPV 16 and 18.<sup>24</sup> In another study, the 2-valent vaccine reduced the incidence of CIN 3 or higher by 87% in women who received all 3 doses and who had no evidence of HPV infection at baseline.<sup>25</sup>

HPV vaccination is expensive. Each shot costs about \$130, plus the cost of administering it. Although the Vaccines for Children program covers the HPV vaccine for uninsured and underinsured children and adolescents under age 19, Medicaid coverage varies from state to state for adults over age 21.

The Advisory Committee on Immunization Practices (ACIP)<sup>26</sup> recommends routine vaccination for:

- Males 11 or 12 years old
- Females ages 9 to 26.

In October 2016, the ACIP approved a 2-dose series given 6 to 12 months apart for patients starting vaccination at ages 9 through 14 years who are not immunocompromised. Others should receive a 3-dose series, with the second dose given 1 to 2 months after the first dose and the third dose given 6 months after the first dose.<sup>27</sup> Previously, 3 doses were recommended for everyone.

**HPV vaccination rates lag behind those of other routine vaccines such as Tdap and meningococcal conjugate**

### Disparities in HPV vaccination rates

HPV vaccination rates among adolescents in the United States increased from 33.6% in 2013 to 41.7% in 2014.<sup>28</sup> However, HPV vaccination rates continue to lag behind those of other routine vaccines, such as Tdap and meningococcal conjugate.

Reagan-Steiner et al<sup>28</sup> reported that more black than white girls age 13 through 17 received at least 1 dose of a 3-dose HPV vaccination series, but more white girls received all 3 doses (70.6% vs 61.6%). In contrast, a meta-analysis by Fisher et al<sup>29</sup> found African American and uninsured women generally less likely to initiate the HPV vaccination series. Kessels et al<sup>30</sup> reported similar findings.

### Barriers to HPV vaccination

Barriers to HPV vaccination can be provider-dependent, parental, or institutional.

Malo et al<sup>31</sup> surveyed Florida Medicaid providers and found that those who participated in the Vaccines for Children program were less likely to cite lack of reimbursement as a barrier to vaccination.

Meites et al<sup>32</sup> surveyed sexually transmitted disease clinics and found that common reasons for not offering HPV vaccine were cost, staff time, and difficulty coordinating follow-up visits to complete the series.

Providers report lack of urgency or lack of perception of cervical cancer as a true public health threat, safety concerns regarding the vaccine, and the inability to coadminister vaccines as barriers.<sup>33</sup>

Studies have shown that relatively few parents (up to 18%) of parents are concerned about the effect of the vaccine on sexual activity.<sup>34</sup> Rather, they are most likely to cite lack of information regarding the vaccine, lack of physician recommendation, and not knowing where to receive the vaccine as barriers.<sup>35,36</sup>

Guerry et al<sup>37</sup> determined that the single most important factor in vaccine initiation was physician recommendation, a finding reiterated in other studies.<sup>35,38</sup> A study in North Carolina identified failure of physician recommendation as one of the missed opportunities for vaccination of young women.<sup>39</sup>

Therefore, the primary care physician, as the initial contact with the child or young adult, holds a responsibility to narrow this

gap. In simply discussing and recommending the vaccine, physicians could increase vaccination rates.

### REPRODUCTIVE HEALTH

Although 80% of women will be infected with HPV in their lifetime, only a small proportion will develop cervical cancer, suggesting there are other cofactors in the progression to cervical cancer.<sup>40</sup>

Given the infectious etiology of cervical cancer, other contributing reproductive health factors have been described. As expected, the number of sexual partners correlates with HPV infection.<sup>41,42</sup> Younger age at first intercourse has been linked to development of cervical neoplasia, consistent with persistent infection leading to neoplasia.<sup>41,42</sup>

Primary care physicians should provide timely and comprehensive sexual education, including information on safe sexual practices and pregnancy prevention.

### Human immunodeficiency virus

In 2010, the estimated rate of new human immunodeficiency virus (HIV) infections in African American women was nearly 20 times greater than in white women.<sup>43</sup> Previous studies have shown a clear relationship between HIV and HPV-associated cancers, including cervical neoplasia and invasive cervical cancer.<sup>44,45</sup>

Women with HIV should receive screening for cervical cancer at the time of diagnosis, 6 months after the initial diagnosis, and annually thereafter.<sup>46</sup>

Conflicting evidence exists regarding the effect of highly active antiretroviral therapy on the incidence of HPV-related disease, so aggressive screening and management of cervical neoplasia is recommended for women with HIV, regardless of CD4+ levels or viral load.<sup>47-49</sup>

### Additional infectious culprits

Coinfection with other sexually transmitted infections, specifically *Chlamydia*, herpes, and HIV, has been associated with cervical neoplasia and invasive cervical cancer. A positive linear association exists between the number of sexually transmitted infections and cervical neoplasia.<sup>50</sup>

**The estimated rate of new HIV infections in African American women was nearly 20 times greater than in white women**



TABLE 2

### Cervical cancer prevention: Tips for the primary care physician

**Have the conversation.** Educate women about cancers related to human papillomavirus (HPV), including cervical cancer.

**Screen all women** for cervical cancer and ensure adequate follow-up of abnormal tests by implementing patient reminders and interactive telephone counseling.

**Routinely offer HPV vaccination** with other required vaccinations. Introduce the HPV vaccine as a vaccine for cancer prevention, as opposed to a vaccine related to sexually transmitted disease.

**Vaccinate all children equally.** Do not offer the vaccine based on perceived risk factors. In other words, do not assume certain children are not at risk.

**Educate patients** about risk factors for cervical cancer.

Women who are seropositive for *Chlamydia*, herpes virus 2, or HPV are at markedly higher risk of invasive cervical cancer

*C trachomatis* is the most common sexually transmitted infection in the United States, with a 6-times higher rate in African American women.<sup>51</sup> Women who are seropositive for *C trachomatis* are at twofold higher risk of developing squamous cell cervical cancer.<sup>52,53</sup> Women who are seropositive for *Chlamydia* infection, herpes virus 2, or HPV are at markedly increased risk of invasive cervical cancer.<sup>50</sup>

#### Tobacco use

The negative impact of smoking on numerous other cancers resulted in investigation of its role in cervical cancer.

Early case-control studies found an association between cervical cancer and smoking,<sup>54</sup> but because these studies did not account for HPV infection status, they could not establish causality. Subsequently, several studies did control for HPV infection; the risk of squamous cervical cancer was twice as high in women who had ever smoked.<sup>55</sup> Furthermore, the more cigarettes smoked per day, the higher the risk of cervical neoplasia.<sup>41,56</sup>

#### REFERENCES

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin* 2014; 64:9–29.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015; 65:5–29.
3. Koh WJ, Greer BE, Abu-Rustum NR, et al. Cervical cancer, version 2.2015. *J Natl Compr Canc Netw* 2015; 13:395–404.

According to the US Centers for Disease Control and Prevention in 2014, the highest prevalence of smoking was among American Indian and Alaskan Native women, 32.5% of whom said they smoked every day, compared with 17.2% of white women and 13.7% of African American women.<sup>57</sup>

#### ■ HOW CAN PRIMARY CARE PHYSICIANS CLOSE THE GAP?

Primary care physicians are the first point of contact for patients of all ages and so can help minimize such disparities. They can tackle 2 important cervical cancer prevention interventions first-hand: vaccination and screening (Table 2), including follow-up of abnormal screening results.

By promoting HPV vaccination to children and young adults, primary care physicians can help prevent cervical cancer. Moreover, primary care physicians will see most adolescents for a nonpreventive health visit, an optimal opportunity to discuss sexual activity practices and HPV vaccination.<sup>58</sup> Including the HPV vaccine as routine with other vaccinations can close the gap.<sup>38</sup>

Screening and treatment of sexually transmitted infection during these visits can affect the risk that future HPV infection will progress to neoplasia or cancer. Persistent lifestyle modification counseling, especially smoking cessation through motivational interviewing, can lessen the risk of cervical cancer neoplasia progression.

Additionally, in light of recent changes in cervical cancer screening guidelines, the primary care physician's role as educator is of utmost importance. In one study, although 99% of women had received a Pap test, 87% could not identify the purpose of the Pap test.<sup>59</sup> The primary care physician's role is perhaps the most influential in preventing disease and, as such, has the greatest impact on a patient's disease process. ■

4. Farley J, Risinger JI, Rose GS, Maxwell GL. Racial disparities in blacks with gynecologic cancers. *Cancer* 2007; 110:234–243.
5. Farley JH, Hines JF, Taylor RR, et al. Equal care ensures equal survival for African-American women with cervical carcinoma. *Cancer* 2001; 91:869–873.
6. Rauh-Hain JA, Clemmer JT, Bradford LS, et al. Racial disparities in cervical cancer survival over time. *Cancer* 2013; 119:3644–3652.

7. Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH. Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. *Gynecol Oncol* 2014; 133:353–361.
8. Patel DA, Barnholtz-Sloan JS, Patel MK, Malone JM Jr, Chuba PJ, Schwartz K. A population-based study of racial and ethnic differences in survival among women with invasive cervical cancer: analysis of surveillance, epidemiology, and end results data. *Gynecol Oncol* 2005; 97:550–558.
9. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. *Arch Pathol Lab Med* 1997; 121:211–224.
10. Walboomers JM, Jacobs M V, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999; 189:12–19.
11. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. *Lancet* 2004; 364:1678–1683.
12. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. *Clin Cancer Res* 2005; 11:4717–4723.
13. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. *N Engl J Med* 1998; 338:423–428.
14. Saslow D, Solomon D, Lawson HW, et al; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *CA Cancer J Clin* 2012; 62:147–172.
15. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. *Obstet Gynecol* 2015; 125:330–337.
16. Massad LS, Einstein MH, Huh WK, et al; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. *J Low Genit Tract Dis* 2013; 17(suppl 1):S1–S27.
17. Sabatino SA, White MC, Thompson TD, Klabunde CN. Cancer screening test use—United States, 2013. *MMWR* 2015; 64:464–468.
18. Benard VB, Lawson HW, Ehemann CR, Anderson C, Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. *Obstet Gynecol* 2005; 105:1323–1328.
19. Eggleston KS, Coker AL, Luchok KJ, Meyer TE. Adherence to recommendations for follow-up to abnormal Pap tests. *Obstet Gynecol* 2007; 109:1332–1341.
20. Peterson NB, Han J, Freund KM. Inadequate follow-up for abnormal Pap smears in an urban population. *J Natl Med Assoc* 2003; 95:825–832.
21. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. *Int J Cancer* 2011; 128:927–935.
22. Hariri S, Unger ER, Powell SE, et al; HPV-IMPACT Working Group. Human papillomavirus genotypes in high-grade cervical lesions in the United States. *J Infect Dis* 2012; 206:1878–1886.
23. Niccolai LM, Russ C, Julian PJ, et al. Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: associations with race, ethnicity, and poverty. *Cancer* 2013; 119:3052–3058.
24. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N Engl J Med* 2007; 356:1915–1927.
25. Paavonen J, Naud P, Salmerón J, et al; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. *Lancet* 2009; 374:301–314.
26. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males—Advisory Committee on Immunization Practices (ACIP), 2011. *MMWR Morb Mortal Wkly Rep* 2011; 60:1705–1708.
27. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep* 2016; 65:1405–1408.
28. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2014. *MMWR Morb Mortal Wkly Rep* 2015; 64:784–792.
29. Fisher H, Trotter CL, Audrey S, MacDonald-Wallis K, Hickman M. Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. *Int J Epidemiol* 2013; 42:896–908.
30. Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, Tooher RL. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. *Vaccine* 2012; 30:3546–3556.
31. Malo TL, Hassani D, Staras SA, Shenkman EA, Giuliano AR, Vadaparampil ST. Do Florida Medicaid providers' barriers to HPV vaccination vary based on VFC program participation? *Matern Child Health J* 2013; 17:609–615.
32. Meites E, Lla E, Hariri S, et al. HPV vaccine implementation in STD clinics—STD Surveillance Network. *Sex Transm Dis* 2012; 39:32–34.
33. Perkins RB, Clark JA. What affects human papillomavirus vaccination rates? A qualitative analysis of providers' perceptions. *Womens Health Issues* 2012; 22:e379–e386.
34. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. *JAMA Pediatr* 2014; 168:76–82.
35. Dorell CG, Yankey D, Santibanez TA, Markowitz LE. Human papillomavirus vaccination series initiation and completion, 2008–2009. *Pediatrics* 2011; 128:830–839.
36. Bastani R, Glenn BA, Tsui J, et al. Understanding suboptimal human papillomavirus vaccine uptake among ethnic minority girls. *Cancer Epidemiol Biomarkers Prev* 2011; 20:1463–1472.
37. Guerry SL, De Rosa CJ, Markowitz LE, et al. Human papillomavirus vaccine initiation among adolescent girls in high-risk communities. *Vaccine* 2011; 29:2235–2241.
38. Hull PC, Williams EA, Khabele D, Dean C, Bond B, Sanderson M. HPV vaccine use among African American girls: qualitative formative research using a participatory social marketing approach. *Gynecol Oncol* 2014; 132(suppl 1):S13–S20.
39. Brewer NT, Gottlieb SL, Reiter PL, et al. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. *Sex Transm Dis* 2011; 38:197–204.
40. Wang SS, Zuna RE, Wentzensen N, et al. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. *Cancer Epidemiol Biomarkers Prev* 2009; 18:113–120.
41. Deacon JM, Evans CD, Yule R, et al. Sexual behaviour

- and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. *Br J Cancer* 2000; 83:1565–1572.
42. **International Collaboration of Epidemiological Studies of Cervical Cancer.** Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. *Cancer Epidemiol Biomarkers Prev* 2009; 18:1060–1069.
43. **Centers for Disease Control and Prevention (CDC).** Estimated HIV incidence in the United States, 2007–2010. HIV Surveillance Supplemental Report 2012; 17(No. 4). [https://www.cdc.gov/hiv/pdf/statistics\\_hsr\\_vol\\_17\\_no\\_4.pdf](https://www.cdc.gov/hiv/pdf/statistics_hsr_vol_17_no_4.pdf). Accessed September 12, 2017.
44. **Frisch M, Biggar RJ, Goedert JJ.** Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. *J Natl Cancer Inst* 2000; 92:1500–1510.
45. **Schäfer A, Friedmann W, Mielke M, Schwartländer B, Koch MA.** The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. *Am J Obstet Gynecol* 1991; 164:593–599.
46. **Phillips AA, Justman JE.** Screening HIV-infected patients for non-AIDS-defining malignancies. *Curr HIV/AIDS Rep* 2009; 6:83–92.
47. **De Vuyst H, Lillo F, Broutet N, Smith JS.** HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. *Eur J Cancer Prev* 2008; 17:545–554.
48. **Palefsky JM.** Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. *Curr Opin Oncol* 2003; 15:382–388.
49. **Adler DH.** The impact of HAART on HPV-related cervical disease. *Curr HIV Res* 2010; 8:493–497.
50. **Castellsagué X, Pawlita M, Roura E, et al.** Prospective seroepidemiologic study on the role of human papillomavirus and other infections in cervical carcinogenesis: evidence from the EPIC cohort. *Int J Cancer* 2014; 135:440–452.
51. **Centers for Disease Control and Prevention (CDC).** 2013 sexually transmitted disease surveillance. [www.cdc.gov/std/stats13/exordium.htm](http://www.cdc.gov/std/stats13/exordium.htm). Accessed September 12, 2017.
52. **Smith JS, Bosetti C, Muñoz N, et al; IARC multicentric case-control study.** *Chlamydia trachomatis* and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. *Int J Cancer* 2004; 111:431–439.
53. **Koskela P, Anttila T, Bjørge T, et al.** *Chlamydia trachomatis* infection as a risk factor for invasive cervical cancer. *Int J Cancer* 2000; 85:35–39.
54. **Office on Smoking and Health (US).** Women and smoking: a report of the Surgeon General: Chapter 3. Health consequences of tobacco use among women. <http://www.ncbi.nlm.nih.gov/books/NBK44312/>. Accessed September 12, 2017.
55. **Plummer M, Herrero R, Franceschi S, et al; IARC Multi-centre Cervical Cancer Study Group.** Smoking and cervical cancer: pooled analysis of the IARC multi-centric case—control study. *Cancer Causes Control* 2003; 14:805–814.
56. **Ho GY, Kadish AS, Burk RD, et al.** HPV 16 and cigarette smoking as risk factors for high-grade cervical intraepithelial neoplasia. *Int J Cancer* 1998; 78:281–285.
57. **Jamal A, Homa DM, O'Connor E, et al.** Current cigarette smoking among adults - United States, 2005-2014. *MMWR Morb Mortal Wkly Rep* 2015; 64:1233–1240.
58. **Nordin JD, Solberg LI, Parker ED.** Adolescent primary care visit patterns. *Ann Fam Med* 2010; 8:511–516.
59. **Lindau ST, Tomori C, Lyons T, Langseth L, Bennett CL, Garcia P.** The association of health literacy with cervical cancer prevention knowledge and health behaviors in a multiethnic cohort of women. *Am J Obstet Gynecol* 2002; 186:938–943.

ADDRESS: Haider Mahdi, MD, Women's Health Institute, A81, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mahdih@ccf.org